Theratechnologies’ Silence Sparks Shareholder Appeal
By lifting the veil of confidentiality, Future Pak hopes to rally Theratechnologies’ shareholders and increase pressure on the board to engage. The announcement, the company says, is designed to “ensure that the board fulfills its duty” in exploring paths to maximize shareholder value.
A Fully Backed, Fast-Moving Bid
The company emphasized that the offer carries no financing contingencies, thanks to backing from Colbeck Capital Management, Future Pak’s strategic financial partner.
If provided with sufficient due diligence access, Future Pak believes it could finalize a definitive agreement within four to six weeks.
Theratechnologies, which is headquartered in Montreal, did not respond to media requests for comment as of Friday.
A Clash of Pharma Visions
Founded in 1977, Future Pak operates as a privately held contract manufacturer and packager of pharmaceutical and nutraceutical products, headquartered in Wixom, Michigan. Meanwhile, Theratechnologies focuses on HIV treatments and is currently expanding into oncology research—two highly specialized therapeutic areas that would complement Future Pak’s manufacturing prowess.
